OUR TECHNOLOGY

Our cell therapy technology uses the power of a person's own immune system to target and attack their cancer. Given that each cell therapy is uniquely designed for each patient, getting the manufacturing process right -- and being able to scale up for thousands of patients -- is a critical step. As one of the first CAR T-cell therapy companies, Kite has relentlessly focused on its state-of-the-art manufacturing capabilities, and has the largest, dedicated in-house cell therapy manufacturing network in the world.

We believe cell therapy has the power to transform cancer care, so we’re pursuing all potential avenues to help bring it to those who need it.

We develop engineered cell therapies that express a chimeric antigen receptor (CAR) T-cell receptor.

CARs are modified proteins composed of two distinct functional components. The first consists of an antibody fragment or target binding domain that allows CARs to recognize targets that are present on the surface of cancer cells. The second provides signals that are designed to rapidly and powerfully activate the T cell to attack cancer cells. We are developing multiple CAR product candidates while continuing to innovate the next generation of CAR-engineered T cells.